Sign In
Buy VERX
$12.91
+0.310 (+2.46%)
At Close: Jul 31, 2026
VERTEX Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
12:31pm, Wednesday, 25'th Mar 2026
SAN DIEGO, March 25, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Vertex, Inc. (NASDAQ: VERX). The investigation focuses on Vertex's execut
Vertex (NASDAQ:VERX) & UiPath (NYSE:PATH) Head to Head Survey
01:31am, Monday, 23'rd Mar 2026
Vertex (NASDAQ: VERX - Get Free Report) and UiPath (NYSE: PATH - Get Free Report) are both mid-cap computer and technology companies, but which is the superior business? We will contrast the two busin
Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?
09:01am, Friday, 20'th Mar 2026
VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals
02:30pm, Thursday, 19'th Mar 2026
Eli Lilly has strong momentum thanks to its leadership in the weight loss market. Vertex Pharmaceuticals' core franchise and newer approvals could drive top-line growth for a long time.
Bamco Inc. NY Makes New Investment in Vertex, Inc. $VERX
03:36am, Tuesday, 17'th Mar 2026
Bamco Inc. NY acquired a new stake in shares of Vertex, Inc. (NASDAQ: VERX) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm acquired 248,042 shares of the
Is Vertex Pharmaceuticals Heading to $600?
09:15pm, Sunday, 15'th Mar 2026
The biotech company is the leader in the cystic fibrosis market and is quickly expanding into other treatment areas. Vertex forecasts its newer medicines may add $500 million to revenue this year.
Vertex Achieves Remarkable Growth, Sets New Industry Standard with ServiceTitan
04:15pm, Thursday, 12'th Mar 2026
Roofing Innovator Propels to Over $600M in Revenue with 30 Acquisitions in Three Years, Leveraging ServiceTitan's Enterprise-Grade Platform Roofing Innovator Propels to Over $600M in Revenue with 30 A
Vertex, Inc. (NASDAQ:VERX) Receives Consensus Rating of “Hold” from Brokerages
02:52am, Wednesday, 11'th Mar 2026
Vertex, Inc. (NASDAQ: VERX - Get Free Report) has received an average rating of "Hold" from the fifteen analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has ra
Investment Firm Sheds 384,000 Shares of VERX Stock, According to Latest SEC Filing
11:52am, Tuesday, 10'th Mar 2026
Reduced holding by 384,415 shares; estimated transaction value of $8.32 million based on quarterly average price Quarter-end position value decreased by $26.01 million, reflecting both share sales and
Vertex passes key test In quest to treat kidney diseases
10:54am, Tuesday, 10'th Mar 2026
Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease.
Vertex Pops On Positive Final-Phase Results For Chronic Kidney Disease Drug
04:42pm, Monday, 09'th Mar 2026
Vertex stock popped late Monday on promising test results for a drug that could treat a chronic autoimmune disease that destroys the kidneys.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetaci
Comparing i3 Verticals (NASDAQ:IIIV) & Vertex (NASDAQ:VERX)
01:11am, Monday, 09'th Mar 2026
Vertex (NASDAQ: VERX - Get Free Report) and i3 Verticals (NASDAQ: IIIV - Get Free Report) are both computer and technology companies, but which is the superior business? We will compare the two busine
Vertex to Participate in Upcoming March Investor Conferences
04:00pm, Thursday, 05'th Mar 2026
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures
10:00am, Thursday, 05'th Mar 2026
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for t
